Advancing a class on top of statins
Investors & Media

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)

$8.12

 0.48 (6.28%)

High$8.19
Low$7.75
Volume41,096
Market Cap$86,340,301

12/13/17  3:59 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $8.12 with a 52 week high of $21.59 and a 52 week low of $7.20.

Gemphire to Present at the Piper Jaffray and LD Micro Investor Conferences

11/22/17

Read More

Gemphire Therapeutics Presents Data at American Heart Association (AHA) Scientific Sessions Showing that Gemcabene Significantly Reduces Atherogenic Remnant Lipoprotein and LDL-C as Add-on to Statins in a Cardiometabolic Population and Reports Third Quarter 2017 Financial Results

11/13/17

Read More

Positive Gemcabene Results in Proof-of-Concept Preclinical NASH Study Presented at The Liver Meeting® 2017

10/23/17

Read More


There are currently no events scheduled.